- Conditions
- Urgency Urinary Incontinence
- Interventions
- Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- PreDiabetes
- Interventions
- Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
- Drug
- Lead sponsor
- Philip Kern
- Other
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
- Interventions
- Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT)
- Drug · Diagnostic Test
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Houston, Texas • Temple, Texas
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 888 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 103
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
- Conditions
- Healthy, Pharmacokinetics of Mirabegron
- Interventions
- mirabegron
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Interventions
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
- Drug
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
- Conditions
- Spinal Cord Injuries, Urinary Bladder, Neurogenic
- Interventions
- Oxybutynin Chloride IR, Mirabegron
- Drug
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
- Interventions
- Mirabegron 50 MG, Mirabegron 25 MG
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Benign Prostatic Hyperplasia, Overactive Bladder
- Interventions
- Mirabegron, Placebo, Tamsulosin Hydrochloride
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 715 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 32
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
- Conditions
- Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
- Interventions
- Mirabegron
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lower Urinary Tract Symptoms, Nocturia
- Interventions
- Mirabegron
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Interventions
- Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
- Drug
- Lead sponsor
- Astellas Pharma Europe B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 121
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 82
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Mirabegron, Tolterodine ER
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 22
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
- Conditions
- Parkinsons Disease
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Daniel Burdick, MD
- Individual
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls
- Interventions
- Pelvic Floor Muscle Training, Mirabegron, Trospium Chloride
- Behavioral · Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 60 Years to 99 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Galveston, Texas